Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Italy.
Eur Rev Med Pharmacol Sci. 2013 Oct;17(19):2660-7.
The introduction of highly active antiretroviral therapy (HAART) has reduced mortality and improved life expectancy of HIV-positive patients. However, increased survival is associated with increased prevalence of comorbidities, such as cardiovascular disease, hepatic and renal disease. Kidney disease, including HIV-associated nephropathy, acute renal failure and chronic kidney disease, represents one of the main causes of morbidity and mortality, especially if associated to other risk factors, i.e. hypertension, diabetes, older age, black race and hepatitis C coinfection. Careful evaluation of renal function may help identifying kidney disease in its early stages. In addition, proper management of hypertension and diabetes is recommended. Even if HAART has changed the natural course of HIV-associated nephropathy, reducing the risk of End-stage Renal Disease (ERDS), some antiretroviral regimens have been related with the development of acute or chronic kidney disease. Further studies are needed to optimize the management of renal disease among HIV-infected patients.
高效抗逆转录病毒疗法(HAART)的引入降低了 HIV 阳性患者的死亡率并提高了其预期寿命。然而,存活期的延长与合并症(如心血管疾病、肝和肾疾病)的患病率增加相关。肾脏疾病,包括 HIV 相关性肾病、急性肾衰竭和慢性肾脏病,是发病率和死亡率的主要原因之一,尤其是如果与其他风险因素(如高血压、糖尿病、年龄较大、黑人和丙型肝炎合并感染)相关时。对肾功能进行仔细评估可能有助于早期发现肾脏疾病。此外,推荐对高血压和糖尿病进行适当的管理。尽管 HAART 改变了 HIV 相关性肾病的自然病程,降低了终末期肾病(ERDS)的风险,但一些抗逆转录病毒方案与急性或慢性肾脏疾病的发展有关。需要进一步研究以优化 HIV 感染患者的肾脏疾病管理。